TapImmune To Collaborate on TB Vaccine with Aeras

JERICHO, NY—(SmallCapNewsRelease)—November 2, 2020, TapImmune, Inc. (OTCBB: TPIV) announced on Monday that they have signed a research collaboration with Aeras, a non-profit product development organization working to develop new tuberculosis vaccines.
The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras with the aim of advancing suitable candidates to clinical development. Aeras will conduct all pre-clinical development studies at their laboratories.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. Next generation smallpox and TB vaccines are currently in preclinical development.
To view the entire press release, please visit http://finance.yahoo.com/news/TapImmune-Inc-Aeras-Start-pz-2099864169.html?x=0&.v=1
SmallCapNewsRelease gainers are Sino-Global Shipping (NASDAQ: SINO) Syms Corp (NASDAQ: SYMS) Phoenix Companies (NYSE: PNX) Codexis, Inc (NASDAQ: CDXS) Magyar Bancorp (NASDAQ: MGYR) Orient Paper, Inc (NYSE: ONP) Silicon Motion Corp (NASDAQ: SIMO) Noranda Aluminum (NYSE: NOR)
SmallCapNewsRelease decliners are Career Education Corp (NASDAQ: CECO) Atrinsica, Inc (NASDAQ: ATRN) ReachLocal, Inc (NASDAQ: RLOC) Amyris, Inc (NASDAQ: AMRS) QuickLogic Corp (NASDAQ: QUIK) Diamond Foods, Inc (NASDAQ: DMND) Novatel Wireless (NASDAQ: NVTL) Hong Kong Highpower (NYSE: HPJ)
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid SmallCapNewsRelease one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send no Faxes or emails.

— WebWireID148670 —

BiotechnologyInfectious Disease ControlMedical / PharmaceuticalsOTC / SmallCapWebWire

Featuring YD Feedwordpress Content Filter Plugin